Pyc Therapeutics Ltd has released a press release.
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- PKD Clinical Trial - Safety Outcomes in Part A
- Sustained Vision Improvement in RP11 Patients
- ADOA Program Initiation of Global Repeat Dose Study
- PMS Program Data Supports Progression to Human Trials
- ADOA Program Progressing to Multiple Dose Study
Later from PYC Therapeutics
- Trading Halt
- PYC Capital Raising Presentation
- PYC Raising up to $653m to Deliver Human Efficacy Data
- Completion of Placement and Institutional Entitlement Offer
- Retail Offer Booklet
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics